Novartis plans to axe 680 employees
Novartis declared plans to lay off approximately 680 staff members in its development organisation on 9 April. The workforce reductions…
Novartis declared plans to lay off approximately 680 staff members in its development organisation on 9 April. The workforce reductions…
Incannex Healthcare is gearing up for an investigational new drug (IND) submission for a Phase IIb generalised anxiety disorder study…
The US Food and Drug Administration (FDA) published a final guidance on how sponsors can charge for new drugs under…
Intellia Therapeutics teased its upcoming goals for several clinical programmes over the next three years, funded by a secure cash…
Innate Pharma announced the removal of a partial clinical hold on its development programme of lacutamab, as per a 4…
In recent years there has been a downward trend in health care provider (HCP) contact in the pharmaceutical industry with…
Despite the shift towards artificial intelligence (AI) in drug discovery and development, AI-focused biotechs still have key hurdles to overcome,…
Codagenix is setting the foundation to capitalise on a year of success for respiratory syncytial virus (RSV) prophylactics with its…
At the American Diabetes Association’s 83rd Scientific Sessions, Boehringer Ingelheim and Novo Nordisk took another step in the obesity arena…
In January, amidst calls to improve patient safety by optimizing licensed drug formulations, the FDA released a draft guidance that…